21/12/2025
🚨 𝐒𝐄𝐑𝐈𝐎𝐔𝐒 𝐌𝐄𝐃𝐈𝐂𝐀𝐋 𝐌𝐈𝐒𝐈𝐍𝐅𝐎𝐑𝐌𝐀𝐓𝐈𝐎𝐍 𝐀𝐋𝐄𝐑𝐓 — as printed on The Times of India newspaper on 20/12/2025
𝐀 𝐟𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐢𝐧𝐜𝐨𝐫𝐫𝐞𝐜𝐭 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐰𝐚𝐬 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 in print media on 20th December, 2025 by reporting the launch of KOLGOTRG's Ovarian Cancer IPIROC trial as 'Cervical Cancer Drug Trial'.
⚠️ 𝐓𝐡𝐢𝐬 𝐢𝐬 𝐅𝐀𝐋𝐒𝐄.
𝐓𝐡𝐞 𝐞𝐯𝐞𝐧𝐭 𝐡𝐞𝐥𝐝 𝐨𝐧 𝟏𝟒 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓 (𝐊𝐨𝐥𝐤𝐚𝐭𝐚) 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝 𝐈𝐏𝐈𝐑𝐎𝐂 – Intermittent PARP Inhibitor Regimen in Ovarian Cancer, a pan-India, ICMR-funded clinical trial for 𝐎𝐕𝐀𝐑𝐈𝐀𝐍 𝐂𝐀𝐍𝐂𝐄𝐑 𝐏𝐀𝐓𝐈𝐄𝐍𝐓𝐒 𝐎𝐍𝐋𝐘.
❌𝐓𝐡𝐞 𝐈𝐏𝐈𝐑𝐎𝐂 𝐭𝐫𝐢𝐚𝐥 𝐢𝐬 𝐍𝐎𝐓 𝐚 𝐭𝐫𝐢𝐚𝐥 𝐰𝐡𝐢𝐜𝐡 𝐢𝐬 𝐮𝐬𝐢𝐧𝐠 𝐏𝐀𝐑𝐏 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐢𝐧 𝐂𝐞𝐫𝐯𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 - Reporting of such erroneous facts constitutes serious medical misinformation and risks direct patient confusion and harm.
Despite providing with clear , written, verified briefing note to media, the published content was totally incorrect, for which the concerned media house bears the sole responsibility.
🔴 𝐖𝐄 𝐅𝐎𝐑𝐌𝐀𝐋𝐋𝐘 𝐃𝐄𝐌𝐀𝐍𝐃 𝐈𝐌𝐌𝐄𝐃𝐈𝐀𝐓𝐄 𝐂𝐎𝐑𝐑𝐄𝐂𝐓𝐈𝐎𝐍 𝐀𝐍𝐃 𝐑𝐄-𝐏𝐔𝐁𝐋𝐈𝐂𝐀𝐓𝐈𝐎𝐍 𝐎𝐅 𝐓𝐇𝐄 𝐀𝐂𝐂𝐔𝐑𝐀𝐓𝐄 𝐈𝐍𝐅𝐎𝐑𝐌𝐀𝐓𝐈𝐎𝐍 𝐈𝐍 𝐓𝐇𝐄 𝐏𝐔𝐁𝐋𝐈𝐂 𝐈𝐍𝐓𝐄𝐑𝐄𝐒𝐓.
Correct statement as officially provided for media printing, ahead of the meeting was as follows:-
“𝘈𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘤𝘰𝘴𝘵𝘭𝘺 𝘤𝘩𝘦𝘮𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘢𝘨𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘱𝘰𝘰𝘳 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴 𝘪𝘴 𝘢 𝘨𝘭𝘰𝘣𝘢𝘭 𝘪𝘴𝘴𝘶𝘦 𝘢𝘴 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘦𝘥 𝘪𝘯 𝘌𝘷𝘦𝘳𝘺 𝘞𝘰𝘮𝘢𝘯 𝘴𝘵𝘶𝘥𝘺- 𝘓𝘰𝘸 𝘢𝘯𝘥 𝘭𝘰𝘸 𝘮𝘪𝘥𝘥𝘭𝘦 𝘪𝘯𝘤𝘰𝘮𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘺 𝘦𝘥𝘪𝘵𝘪𝘰𝘯, 𝘸𝘩𝘪𝘤𝘩 𝘸𝘢𝘴 𝘳𝘦𝘤𝘦𝘯𝘵𝘭𝘺 𝘱𝘶𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘱𝘳𝘦𝘴𝘵𝘪𝘨𝘪𝘰𝘶𝘴 𝘫𝘰𝘶𝘳𝘯𝘢𝘭 𝘓𝘢𝘯𝘤𝘦𝘵, 𝘸𝘩𝘦𝘳𝘦 𝘐𝘯𝘥𝘪𝘢 𝘱𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦𝘥 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘒𝘰𝘭𝘬𝘢𝘵𝘢 𝘎𝘺𝘯𝘦𝘤𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘛𝘳𝘪𝘢𝘭𝘴 𝘢𝘯𝘥 𝘛𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘎𝘳𝘰𝘶𝘱 (𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎).
𝘊𝘳𝘦𝘢𝘵𝘦𝘥 𝘪𝘯 2018, 𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘱𝘪𝘰𝘯𝘦𝘦𝘳𝘪𝘯𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴 𝘢𝘯𝘥 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯 𝘸𝘰𝘮𝘦𝘯'𝘴 𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘴 𝘵𝘩𝘦 𝘰𝘯𝘭𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘨𝘳𝘰𝘶𝘱 𝘧𝘳𝘰𝘮 𝘐𝘯𝘥𝘪𝘢 𝘢𝘯𝘥 𝘚𝘰𝘶𝘵𝘩 𝘈𝘴𝘪𝘢 𝘵𝘰 𝘣𝘦 𝘢 𝘮𝘦𝘮𝘣𝘦𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘨𝘭𝘰𝘣𝘢𝘭 𝘤𝘰𝘯𝘴𝘰𝘳𝘵𝘪𝘶𝘮 𝘎𝘺𝘯 𝘊𝘢𝘯𝘤𝘦𝘳 𝘐𝘯𝘵𝘦𝘳𝘨𝘳𝘰𝘶𝘱 𝘰𝘳 𝘎𝘊𝘐𝘎. 𝘈 𝘭𝘢𝘯𝘥𝘮𝘢𝘳𝘬 𝘴𝘵𝘶𝘥𝘺 𝘐𝘗𝘐𝘙𝘖𝘊 (𝘐𝘯𝘵𝘦𝘳𝘮𝘪𝘵𝘵𝘦𝘯𝘵 𝘗𝘈𝘙𝘗 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘰𝘳 𝘙𝘦𝘨𝘪𝘮𝘦𝘯 𝘪𝘯 𝘖𝘷𝘢𝘳𝘪𝘢𝘯 𝘊𝘢𝘯𝘤𝘦𝘳) 𝘸𝘢𝘴 𝘭𝘢𝘶𝘯𝘤𝘩𝘦𝘥 𝘵𝘰𝘥𝘢𝘺 𝘰𝘧𝘧𝘪𝘤𝘪𝘢𝘭𝘭𝘺. 𝘛𝘩𝘪𝘴 𝘵𝘳𝘪𝘢𝘭 𝘸𝘢𝘴 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘦𝘥 𝘢𝘧𝘵𝘦𝘳 𝘺𝘦𝘢𝘳𝘴 𝘰𝘧 𝘱𝘪𝘰𝘯𝘦𝘦𝘳𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘣𝘺 𝘋𝘳 𝘈𝘴𝘪𝘮𝘢 𝘔𝘶𝘬𝘩𝘰𝘱𝘢𝘥𝘩𝘺𝘢𝘺, 𝘊𝘰𝘯𝘴𝘶𝘭𝘵𝘢𝘯𝘵 𝘎𝘺𝘯 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘪𝘴𝘵 𝘢𝘯𝘥 𝘤𝘭𝘪𝘯𝘪𝘤𝘪𝘢𝘯 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘴𝘵 𝘢𝘯𝘥 𝘩𝘦𝘳 𝘵𝘦𝘢𝘮. 𝘍𝘶𝘯𝘥𝘦𝘥 𝘣𝘺 𝘐𝘊𝘔𝘙 (𝘐𝘯𝘥𝘪𝘢𝘯 𝘊𝘰𝘶𝘯𝘤𝘪𝘭 𝘰𝘧 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩) , 𝘵𝘩𝘪𝘴 𝘵𝘳𝘪𝘢𝘭 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘰𝘱𝘦𝘯 𝘢𝘤𝘳𝘰𝘴𝘴 𝘢𝘭𝘭 𝘴𝘵𝘢𝘵𝘦𝘴 𝘪𝘯 𝘐𝘯𝘥𝘪𝘢 𝘢𝘯𝘥 𝘴𝘰𝘮𝘦 𝘴𝘪𝘵𝘦𝘴 𝘢𝘣𝘳𝘰𝘢𝘥. 𝘐𝘵 𝘸𝘪𝘭𝘭 𝘢𝘥𝘥𝘳𝘦𝘴𝘴 𝘢 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 𝘪𝘴𝘴𝘶𝘦 𝘰𝘯 𝘩𝘰𝘸 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘥𝘰𝘴𝘦 𝘰𝘧 𝘤𝘩𝘦𝘮𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘥𝘳𝘶𝘨 𝘗𝘈𝘙𝘗 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘰𝘳 𝘸𝘪𝘵𝘩 𝘭𝘰𝘸𝘦𝘳 𝘴𝘪𝘥𝘦 𝘦𝘧𝘧𝘦𝘤𝘵𝘴 𝘢𝘯𝘥 𝘭𝘰𝘸 𝘤𝘰𝘴𝘵 𝘵𝘰 𝘳𝘪𝘨𝘩𝘵 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘋𝘳 𝘈𝘴𝘪𝘮𝘢 𝘔𝘶𝘬𝘩𝘰𝘱𝘢𝘥𝘩𝘺𝘢𝘺, 𝘋𝘪𝘳𝘦𝘤𝘵𝘰𝘳 𝘒𝘰𝘭𝘎𝘖𝘛𝘙𝘎 𝘢𝘯𝘥 𝘙𝘖𝘊𝘒 (𝘙𝘦𝘨𝘪𝘰𝘯𝘢𝘭 𝘖𝘷𝘢𝘳𝘪𝘢𝘯 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘯𝘵𝘳𝘦 𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎) 𝘵𝘩𝘢𝘯𝘬𝘦𝘥 𝘐𝘊𝘔𝘙 𝘧𝘰𝘳 𝘧𝘶𝘯𝘥𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘪𝘯𝘪𝘵𝘪𝘢𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘳𝘦𝘲𝘶𝘦𝘴𝘵𝘦𝘥 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘪𝘴𝘵𝘴 𝘢𝘭𝘭 𝘢𝘤𝘳𝘰𝘴𝘴 𝘐𝘯𝘥𝘪𝘢 𝘵𝘰 𝘪𝘯𝘧𝘰𝘳𝘮 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘪𝘴 𝘴𝘵𝘶𝘥𝘺 𝘸𝘩𝘦𝘳𝘦 𝘧𝘳𝘦𝘦 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘢 𝘤𝘰𝘴𝘵𝘭𝘺 𝘢𝘯𝘵𝘪-𝘤𝘢𝘯𝘤𝘦𝘳 𝘥𝘳𝘶𝘨 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘥 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘢 𝘵𝘳𝘪𝘢𝘭. 𝘚𝘩𝘦 𝘢𝘥𝘥𝘳𝘦𝘴𝘴𝘦𝘥 𝘵𝘩𝘦 𝘪𝘴𝘴𝘶𝘦 𝘰𝘧 𝘣𝘢𝘳𝘳𝘪𝘦𝘳𝘴 𝘸𝘩𝘦𝘳𝘦 𝘴𝘰𝘮𝘦 𝘱𝘩𝘺𝘴𝘪𝘤𝘪𝘢𝘯𝘴 𝘰𝘳 𝘤𝘢𝘯𝘤𝘦𝘳 𝘤𝘦𝘯𝘵𝘳𝘦𝘴 𝘥𝘰 𝘯𝘰𝘵 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘱𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦 𝘪𝘯 𝘴𝘶𝘤𝘩 𝘢𝘤𝘢𝘥𝘦𝘮𝘪𝘤 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴, 𝘸𝘩𝘦𝘳𝘦 𝘱𝘰𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘤𝘢𝘯 𝘴𝘶𝘣𝘴𝘵𝘢𝘯𝘵𝘪𝘢𝘭𝘭𝘺 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘧𝘳𝘰𝘮 𝘯𝘦𝘸𝘦𝘳 𝘪𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘴. 𝘚𝘩𝘦 𝘢𝘭𝘴𝘰 𝘵𝘩𝘢𝘯𝘬𝘦𝘥 𝘚𝘶𝘳𝘢𝘬𝘴𝘩𝘢 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴 𝘢𝘯𝘥 𝘥𝘪𝘳𝘦𝘤𝘵𝘰𝘳𝘴 𝘋𝘳 𝘚𝘰𝘮𝘯𝘢𝘵𝘩 𝘊𝘩𝘢𝘵𝘵𝘦𝘳𝘫𝘦𝘦 𝘢𝘯𝘥 𝘙𝘪𝘵𝘶 𝘔𝘪𝘵𝘵𝘢𝘭 𝘧𝘰𝘳 𝘪𝘮𝘮𝘦𝘯𝘴𝘦𝘭𝘺 𝘧𝘢𝘤𝘪𝘭𝘪𝘵𝘢𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘴𝘦𝘵𝘵𝘪𝘯𝘨 𝘶𝘱 𝘰𝘧 𝘵𝘩𝘦 𝘴𝘵𝘶𝘥𝘺 𝘣𝘺 𝘱𝘳𝘰𝘷𝘪𝘥𝘪𝘯𝘨 𝘴𝘱𝘢𝘤𝘦 𝘧𝘰𝘳 𝘙𝘖𝘊𝘒 𝘢𝘯𝘥 𝘱𝘳𝘰𝘷𝘪𝘴𝘪𝘰𝘯 𝘰𝘧 𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘺 𝘧𝘢𝘤𝘪𝘭𝘪𝘵𝘪𝘦𝘴 𝘧𝘰𝘳 𝘣𝘪𝘰𝘣𝘢𝘯𝘬𝘪𝘯𝘨 𝘢𝘯𝘥 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘹𝘵 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳 𝘢𝘴𝘴𝘢𝘺𝘴 𝘭𝘪𝘬𝘦 𝘵𝘩𝘦 𝘢𝘤𝘢𝘥𝘦𝘮𝘪𝘤 𝘏𝘙𝘋 𝘢𝘯𝘥 𝘗𝘈𝘙𝘗 𝘢𝘴𝘴𝘢𝘺 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘴𝘦𝘭𝘦𝘤𝘵𝘪𝘰𝘯, 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘢𝘯 𝘶𝘯𝘪𝘲𝘶𝘦 𝘙&𝘋 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎. 𝘚𝘩𝘦 𝘢𝘭𝘴𝘰 𝘵𝘩𝘢𝘯𝘬𝘦𝘥 𝘰𝘵𝘩𝘦𝘳 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘉𝘋𝘙 𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭𝘴 𝘧𝘰𝘳 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 1𝘴𝘵 𝘱𝘩𝘢𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘴𝘵𝘶𝘥𝘺 𝘢𝘯𝘥 𝘱𝘳𝘰𝘷𝘪𝘥𝘪𝘯𝘨 𝘗𝘢𝘯-𝘐𝘯𝘥𝘪𝘢 𝘤𝘰-𝘰𝘳𝘥𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘗𝘈𝘙𝘗 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘰𝘳 𝘳𝘶𝘤𝘢𝘱𝘢𝘳𝘪𝘣. '𝘈𝘤𝘢𝘥𝘦𝘮𝘪𝘢-𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦' - 𝘋𝘳 𝘔𝘶𝘬𝘩𝘰𝘱𝘢𝘥𝘩𝘺𝘢𝘺 𝘦𝘹𝘱𝘭𝘢𝘪𝘯𝘦𝘥 ,𝘤𝘪𝘵𝘪𝘯𝘨 𝘰𝘵𝘩𝘦𝘳 𝘦𝘹𝘢𝘮𝘱𝘭𝘦𝘴 𝘰𝘧 𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘨𝘰𝘷𝘦𝘳𝘯𝘮𝘦𝘯𝘵𝘢𝘭 𝘣𝘰𝘥𝘪𝘦𝘴 , 𝘭𝘪𝘬𝘦 𝘵𝘩𝘦 𝘊𝘚𝘐𝘙 𝘏𝘊𝘗 40 𝘱𝘳𝘰𝘨𝘳𝘢𝘮 𝘪𝘯 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘧𝘰𝘳 𝘸𝘰𝘮𝘦𝘯'𝘴 𝘤𝘢𝘯𝘤𝘦𝘳 𝘪𝘯 𝘐𝘯𝘥𝘪𝘢 𝘢𝘯𝘥 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘚𝘶𝘳𝘢𝘬𝘴𝘩𝘢 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴 𝘓𝘵𝘥 𝘢𝘯𝘥 𝘊𝘦𝘱𝘩𝘦𝘪𝘥 𝘨𝘭𝘰𝘣𝘢𝘭 𝘧𝘰𝘳 𝘢𝘯 𝘪𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘸𝘢𝘳𝘥 𝘸𝘪𝘯𝘯𝘪𝘯𝘨 𝘤𝘦𝘳𝘷𝘪𝘤𝘢𝘭 𝘤𝘢𝘯𝘤𝘦𝘳 𝘴𝘤𝘳𝘦𝘦𝘯𝘪𝘯𝘨 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘪𝘯 𝘛𝘦𝘢 𝘨𝘢𝘳𝘥𝘦𝘯𝘴 𝘰𝘧 𝘋𝘢𝘳𝘫𝘦𝘦𝘭𝘪𝘯𝘨 𝘥𝘪𝘴𝘵𝘳𝘪𝘤𝘵 𝘸𝘪𝘵𝘩 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘭𝘰𝘨𝘪𝘴𝘵𝘪𝘤𝘢𝘭 𝘧𝘳𝘰𝘮 𝘔𝘪𝘯𝘪𝘴𝘵𝘳𝘺 𝘰𝘧 𝘏𝘦𝘢𝘭𝘵𝘩 𝘢𝘯𝘥 𝘧𝘢𝘮𝘪𝘭𝘺 𝘞𝘦𝘭𝘧𝘢𝘳𝘦, 𝘎𝘰𝘷𝘵 𝘰𝘧 𝘞𝘦𝘴𝘵 𝘉𝘦𝘯𝘨𝘢𝘭 𝘢𝘯𝘥 𝘭𝘰𝘤𝘢𝘭 𝘕𝘎𝘖, 𝘔𝘢𝘯𝘪𝘴𝘩𝘢 𝘕𝘢𝘯𝘥𝘪 𝘧𝘰𝘶𝘯𝘥𝘢𝘵𝘪𝘰𝘯.
𝘛𝘩𝘦 𝘦𝘷𝘦𝘯𝘵, 𝘩𝘦𝘭𝘥 𝘪𝘯 𝘒𝘰𝘭𝘬𝘢𝘵𝘢 𝘰𝘯 14𝘵𝘩 𝘋𝘦𝘤𝘦𝘮𝘣𝘦𝘳 2025, 𝘸𝘢𝘴 𝘨𝘳𝘢𝘤𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘱𝘳𝘦𝘴𝘦𝘯𝘤𝘦 𝘰𝘧 𝘴𝘦𝘷𝘦𝘳𝘢𝘭 𝘸𝘰𝘳𝘭𝘥 𝘭𝘦𝘢𝘥𝘦𝘳'𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘧𝘪𝘦𝘭𝘥 𝘰𝘧 𝘸𝘰𝘮𝘦𝘯'𝘴 𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘯𝘥 𝘒𝘖𝘓𝘎𝘖𝘛𝘙𝘎 𝘧𝘦𝘭𝘪𝘤𝘪𝘵𝘢𝘵𝘦𝘥 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴 𝘢𝘯𝘥 𝘨𝘭𝘰𝘣𝘢𝘭 𝘮𝘦𝘯𝘵𝘰𝘳𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦𝘪𝘳 𝘶𝘯𝘸𝘢𝘷𝘦𝘳𝘪𝘯𝘨 𝘴𝘶𝘱𝘱𝘰𝘳𝘵, 𝘸𝘩𝘪𝘭𝘦 𝘢𝘤𝘬𝘯𝘰𝘸𝘭𝘦𝘥𝘨𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘪𝘷𝘰𝘵𝘢𝘭 𝘳𝘰𝘭𝘦 𝘱𝘭𝘢𝘺𝘦𝘥 𝘣𝘺 𝘎𝘰𝘷𝘦𝘳𝘯𝘮𝘦𝘯𝘵𝘢𝘭 𝘧𝘶𝘯𝘥𝘪𝘯𝘨 𝘣𝘰𝘥𝘪𝘦𝘴 𝘭𝘪𝘬𝘦 𝘐𝘊𝘔𝘙 𝘧𝘰𝘳 𝘵𝘩𝘦𝘪𝘳 𝘷𝘪𝘴𝘪𝘰𝘯 𝘪𝘯 𝘴𝘩𝘢𝘱𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘥𝘪𝘳𝘦𝘤𝘵𝘪𝘰𝘯 𝘪𝘯 𝘐𝘯𝘥𝘪𝘢.”
Inaccurate reporting of clinical trials undermines patient safety, public trust, and ethical medical communication.
𝐈𝐌𝐌𝐄𝐃𝐈𝐀𝐓𝐄 𝐑𝐄𝐂𝐓𝐈𝐅𝐈𝐂𝐀𝐓𝐈𝐎𝐍 𝐈𝐒 𝐃𝐄𝐌𝐀𝐍𝐃𝐄𝐃.
The Times of India KolGo Trg Kolkata Gynecological Oncology Trials & Translational Research Group
